drugset / Trial / NCT03016741
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer
Non-randomizedParallel-groupOpen-labelSupportive care
Summary
This clinical trial studies cognitive function in men with prostate cancer treated with androgen receptor directed therapies such as abiraterone acetate and enzalutamide. The investigators use MRI imaging (non-invasive, non-contrast) to see whether there are changes in brain structure or activity related to treatment that may be related to changes in cognitive function. The investigators are also looking for genetic variations that might make patients more or less sensitive to cognitive changes during treatment for prostate cancer.
Timeline
- Start
- 2017-03-31
- Primary completion
- 2023-01-04
- Completion
- 2029-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Abiraterone acetate | Small molecule | — | Oral |
| Subject | Enzalutamide | Other / unclassified | — | Oral |
| Background | Prednisone | Other / unclassified | — | Oral |